Innovation Kyoto 2021 Investment Limited Partnership ("KYOTO-iCAP No.2 Fund"), with Kyoto University Innovation Capital Corporation ("Kyoto iCAP") (Head Office: Sakyo-ku, Kyoto; Representative Director: Kimi Kusumi) as general partner, has made a new investment in Eurus Therapeutics Co. (Head office: Fujisawa City, Kanagawa Prefecture; Representative Director: Takato Noumi).

Outline of this investment
Eurus Therapeutics is a drug discovery venture founded in February 2021 based on an idea for a new gene-related therapy. By utilizing the technology and knowledge of national universities, we will accelerate our business.

New technologies for gene-related therapies are being applied to various genetic diseases, starting with the discovery of the CRISPR/Cas9 system. On the other hand, the use of CRISPR/Cas9 system still has many technical and therapeutic application issues, and from a business perspective, it is necessary to conclude a license agreement with a U.S. research institution. In addition, there have been a number of cases, both domestic and international, where companies with proprietary technologies have formed large alliances prior to entering clinical trials, making this an area that is attracting considerable attention.

In light of these developments, Kyoto iCAP highly evaluated the potential of Eurus Therapeutics' novel gene-related therapy and made a new investment of 20 million yen through a third-party allocation of new shares. In addition to Kyoto iCAP, the new investment was made by an investment limited partnership managed by Nissay Capital Corporation and individual investors.

Overview of Eurus Therapeutics, Inc.

Establishment	February 2021
Business	Development of novel gene-related therapies
Head Office Location	Fujisawa City, Kanagawa Prefecture
President & CEO	Takahito Nohmi